Experienced in Classical Hodgkin Lymphoma

Dr. Robert K. Stuart

Hematology Oncology | Transplant Surgery
171 Ashley Ave, 
Charleston, SC 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Classical Hodgkin Lymphoma
171 Ashley Ave, 
Charleston, SC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Stuart is a Hematologist Oncology specialist and a Transplant Surgeon in Charleston, South Carolina. Dr. Stuart is rated as an Experienced provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 49 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Transplant Surgery
Licenses
Internal Medicine in SC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Independent Health
  • EPO
  • POS
  • PPO

Locations

171 Ashley Ave, Charleston, SC 29425

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: SEA-CD70
Study Phase: Phase 1
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: April 17, 2025
Intervention Type: Drug
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Lenalidomide
Study Phase: Phase 3
Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML
Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML
Enrollment Status: Completed
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: Cytarabine, Vosaroxin
Study Phase: Phase 2
A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy
A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy
Enrollment Status: Completed
Publish Date: July 27, 2023
Intervention Type: Drug
Study Drug: Cytarabine
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: November 21, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: August 13, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
Enrollment Status: Unknown
Publish Date: June 29, 2017
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

49 Total Publications

Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy.
Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy.
Journal: Blood advances
Published: May 21, 2024
Similar Doctors
Distinguished in Classical Hodgkin Lymphoma
Dr. Brian T. Hess
Hematology | Oncology | Hematology Oncology
Distinguished in Classical Hodgkin Lymphoma
Dr. Brian T. Hess
Hematology | Oncology | Hematology Oncology

University Medical Associates Of The Medical University Of South Carol

171 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Hess is a Hematologist and an Oncologist in Charleston, South Carolina. Dr. Hess is rated as an Elite provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Hess is currently accepting new patients.

Distinguished in Classical Hodgkin Lymphoma
Dr. James E. Turner
Hematology Oncology | Hematology | Oncology
Distinguished in Classical Hodgkin Lymphoma
Dr. James E. Turner
Hematology Oncology | Hematology | Oncology

Beaufort County Memorial Hospital

989 Ribaut Rd, Suite 310, 
Beaufort, SC 
 (50.2 miles away)
843-522-7350
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Turner is a Hematologist Oncology specialist and a Hematologist in Beaufort, South Carolina. Dr. Turner is rated as a Distinguished provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Colorectal Cancer, and Lynch Syndrome. Dr. Turner is currently accepting new patients.

Advanced in Classical Hodgkin Lymphoma
Dr. Brian M. Lingerfelt
Hematology Oncology | Hematology | Oncology
Advanced in Classical Hodgkin Lymphoma
Dr. Brian M. Lingerfelt
Hematology Oncology | Hematology | Oncology

Bon Secours St Francis Xavier Hospital Inc

2085 Henry Tecklenburg Dr, 
Charleston, SC 
 (5.7 miles away)
843-577-6957
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brian Lingerfelt is a Hematologist Oncology specialist and a Hematologist in Charleston, South Carolina. Dr. Lingerfelt is rated as a Distinguished provider by MediFind in the treatment of Classical Hodgkin Lymphoma. His top areas of expertise are Hodgkin Lymphoma, Childhood Iron Deficiency Anemia, Familial Colorectal Cancer, and Paget Disease of the Breast. Dr. Lingerfelt is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stuart's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 24 Advanced Conditions
View All 54 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile